Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®.

From COOK MEDICAL INC. 4 Feb 2015

Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color.

20 Oct 2014

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.

16 Sep 2014

Drug-eluting peripheral stent from Cook Medical selected as a top 10 game-changing health technology for 2014

As announced at the 2014 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium, the Canadian Network for Environmental Scanning in Health (CNESH) has selected Cook Medical’s Zilver® PTX® drug-eluting peripheral stent as a top 10 game-changing health technology for 2014. The CNESH top 10 list is designed to encourage the adoption and use of effective, safe health technologies in Canada.

From COOK MEDICAL INC. 24 Jul 2014

Zilver® PTX® drug-eluting stent from Cook Medical receives positive one-year follow-up results

One-year follow-up data from 907 Japanese patients who received the Zilver® PTX® drug-eluting stent showed positive results in keeping open the superficial femoral artery (SFA). The postmarket surveillance (PMS) study, designed to evaluate the stent’s performance in real-world patient use, was presented at the 2014 Euro PCR meeting.

From COOK MEDICAL INC. 29 May 2014

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week.

23 May 2014

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI® trial.

23 May 2014

BIOTRONIK's Entovis pacemaker system gets FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration has granted approval for its Entovis pacemaker system with ProMRI technology.

7 May 2014

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX) reported favorable results in studies related to cardiac resynchronization therapy (CRT), platinum chromium stent platforms and transcatheter aortic valve replacement (TAVR).

2 Apr 2014

FDA approves expansion of BIOTRONIK's ongoing ProMRI trial

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration has approved the expansion of BIOTRONIK's ongoing ProMRI trial. The new phase of the trial (Phase C) will study the company's ProMRI technology in implantable cardioverter-defibrillator (ICD) devices.

14 Mar 2014

Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott.

4 Feb 2014

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

As co-ordinator of the European project ‘ReBioStent’, Ceram, the international materials technology company, is pleased to announce that the project, to develop new biomaterials and new arterial stents, has been awarded Euro 5.874M by the European Union.

20 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

Equations help explain key parameters of stents that combat artherosclerosis

Coronary heart disease accounts for 18% of deaths in the United States every year. The disease results from a blockage of one or more arteries that supply blood to the heart muscle.

9 Dec 2013

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Boston Scientific Corporation and The Medicines Company announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System.

6 Dec 2013

Svelte completes enrollment in drug-eluting coronary stent Integrated Delivery System study

Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.

From Medtronic 14 Nov 2013

Six-month surgery delay ‘acceptable’ after DES implantation

The recommendation to delay noncardiac surgery for a year after receipt of a drug-eluting stent, compared with just 6 weeks for a bare-metal stent, may be too conservative, suggests research indicating that stent type does not influence the longer term risk for major adverse cardiac events.

14 Oct 2013

Drug Eluting Stent News and Research

Further Reading